Liver disease related to alpha1-antitrypsin ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Liver disease related to alpha1-antitrypsin deficiency in french children: the defi-alpha cohort
Auteur(s) :
Ruiz, Mathias [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Lacaille, Florence [Auteur]
Gastro-Entérologie, Hépatologie et Nutrition pédiatriques [CHU Necker - Enfants Malades [AP-HP]]
Berthiller, Julien [Auteur]
Pôle Information Médicale Evaluation Recherche [IMER]
Joly, Philippe [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Dumortier, Jerome [Auteur]
Hospices Civils de Lyon [HCL]
Aumar, Madeleine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bridoux-Henno, Laure [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Jacquemin, Emmanuel [Auteur]
Université Paris-Sud - Paris 11 [UP11]
Lamireau, Thierry [Auteur]
Université de Bordeaux [UB]
Broue, Pierre [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Rivet, Christine [Auteur]
Hospices Civils de Lyon [HCL]
Belmalih, Abdelouahed [Auteur]
Hospices Civils de Lyon [HCL]
Restier, Lioara [Auteur]
Hospices Civils de Lyon [HCL]
Chapuis-Cellier, Colette [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Bouchecareilh, Marion [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Lachaux, Alain [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Université Claude Bernard Lyon 1 [UCBL]
Lacaille, Florence [Auteur]
Gastro-Entérologie, Hépatologie et Nutrition pédiatriques [CHU Necker - Enfants Malades [AP-HP]]
Berthiller, Julien [Auteur]
Pôle Information Médicale Evaluation Recherche [IMER]
Joly, Philippe [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Dumortier, Jerome [Auteur]
Hospices Civils de Lyon [HCL]
Aumar, Madeleine [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Bridoux-Henno, Laure [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Jacquemin, Emmanuel [Auteur]
Université Paris-Sud - Paris 11 [UP11]
Lamireau, Thierry [Auteur]
Université de Bordeaux [UB]
Broue, Pierre [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Rivet, Christine [Auteur]
Hospices Civils de Lyon [HCL]
Belmalih, Abdelouahed [Auteur]
Hospices Civils de Lyon [HCL]
Restier, Lioara [Auteur]
Hospices Civils de Lyon [HCL]
Chapuis-Cellier, Colette [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Bouchecareilh, Marion [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Lachaux, Alain [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Titre de la revue :
Liver International
Nom court de la revue :
Liver Int.
Numéro :
39
Pagination :
1136-1146
Date de publication :
2019-06
ISSN :
1478-3231
Mot(s)-clé(s) en anglais :
liver enzyme
liver transplantation
metabolic liver disease
cirrhosis
liver transplantation
metabolic liver disease
cirrhosis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
To identify prognostic factors for liver disease in children with alpha-1 antitrypsin deficiency, irrespective of phenotype, using the DEFI-ALPHA cohort.
Retrospective, then prospective from 2010, multicentre study including ...
Lire la suite >To identify prognostic factors for liver disease in children with alpha-1 antitrypsin deficiency, irrespective of phenotype, using the DEFI-ALPHA cohort. Retrospective, then prospective from 2010, multicentre study including children known to have alpha-1 antitrypsin blood concentration below 0.8 g/L, born in France since 1989. Clinical and biological data were collected. Liver disease was classified as "severe" (portal hypertension, liver failure, liver transplantation or death); "moderate" (persistent abnormal liver biology without portal hypertension); and "mild/none" (normal or almost normal liver biology and native liver). Prognostic factors for severe liver disease were evaluated using a Cox semiparametric model. In January 2017, 153 patients from 19 centres had been included; genotypes were PIZZ in 81.9%, PISZ in 8.1%, other in 10.0%. Mean ± SD follow-up was 4.7 ± 2.1 years. Half of patients had moderate liver disease. Twenty-eight children (18.3%) had severe liver disease (mean age 2.5 years, range: 0-11.6): diagnosis of alpha-1 antitrypsin deficiency was made before two months of age in 65.4%, genotypes were PIZZ in 25 (89.3%), PISZ in 2, PIMlike Alpha-1 antitrypsin-deficient patients presenting with neonatal cholestasis were likely to develop severe liver disease. Some patients with non-homozygous ZZ genotype can develop severe liver disease, such as PISZ and M variants, when associated with predisposing factors. Further genetic studies will help to identify other factors involved in the development of liver complications.Lire moins >
Lire la suite >To identify prognostic factors for liver disease in children with alpha-1 antitrypsin deficiency, irrespective of phenotype, using the DEFI-ALPHA cohort. Retrospective, then prospective from 2010, multicentre study including children known to have alpha-1 antitrypsin blood concentration below 0.8 g/L, born in France since 1989. Clinical and biological data were collected. Liver disease was classified as "severe" (portal hypertension, liver failure, liver transplantation or death); "moderate" (persistent abnormal liver biology without portal hypertension); and "mild/none" (normal or almost normal liver biology and native liver). Prognostic factors for severe liver disease were evaluated using a Cox semiparametric model. In January 2017, 153 patients from 19 centres had been included; genotypes were PIZZ in 81.9%, PISZ in 8.1%, other in 10.0%. Mean ± SD follow-up was 4.7 ± 2.1 years. Half of patients had moderate liver disease. Twenty-eight children (18.3%) had severe liver disease (mean age 2.5 years, range: 0-11.6): diagnosis of alpha-1 antitrypsin deficiency was made before two months of age in 65.4%, genotypes were PIZZ in 25 (89.3%), PISZ in 2, PIMlike Alpha-1 antitrypsin-deficient patients presenting with neonatal cholestasis were likely to develop severe liver disease. Some patients with non-homozygous ZZ genotype can develop severe liver disease, such as PISZ and M variants, when associated with predisposing factors. Further genetic studies will help to identify other factors involved in the development of liver complications.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2024-01-30T10:27:37Z
2024-04-05T09:24:35Z
2024-04-05T09:24:35Z